• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

369
66
48
46
21

COUNTRY

45
12
6
5
5

PRICE

301
485
901
1,339

PUBLISHED

24
128
424
1,339

PRODUCT TYPE

1,306
17
11
5

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Lewy body Dementia - Pipeline Review, H1 2014

Lewy body Dementia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Lewy body Dementia - Pipeline Review, H1 2014’, provides an overview of the Lewy body Dementia’s therapeutic pipeline. This...

March 2014
FROM

Opium (Opioid) Addiction - Pipeline Review, H1 2014

Opium (Opioid) Addiction - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H1 2014’, provides an overview of the Opium (Opioid) Addiction’s therapeutic...

March 2014
FROM

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014’, provides an overview...

March 2014
FROM

RHB-103 (Migraine) - Forecast and Market Analysis to 2023

RHB-103 (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose...

March 2014
FROM

Anti-Epileptics (Migraine) - Forecast and Market Analysis to 2023

Anti-Epileptics (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected...

March 2014
FROM

MK-1602 (Migraine) - Forecast and Market Analysis to 2023

MK-1602 (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose...

March 2014
FROM

Autism - Pipeline Review, H1 2014

Autism - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Autism - Pipeline Review, H1 2014’, provides an overview of the Autism’s therapeutic pipeline. This report provides comprehensive...

March 2014
FROM

Zecuity (Migraine) - Forecast and Market Analysis to 2023

Zecuity (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose...

March 2014
FROM

PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected...

March 2014
FROM

Acute Ischemic Stroke - Pipeline Review, H1 2014

Acute Ischemic Stroke - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Acute Ischemic Stroke - Pipeline Review, H1 2014’, provides an overview of the Acute Ischemic Stroke’s therapeutic...

March 2014
FROM

Postherpetic Neuralgia - Pipeline Review, H1 2014

Postherpetic Neuralgia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Postherpetic Neuralgia - Pipeline Review, H1 2014’, provides an overview of the Postherpetic Neuralgia’s therapeutic...

March 2014
FROM

Beta Blockers (Migraine) - Forecast and Market Analysis to 2023

Beta Blockers (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to...

March 2014
FROM

Botox (Migraine) - Forecast and Market Analysis to 2023

Botox (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity...

March 2014
FROM

AVP-825 (Migraine) - Forecast and Market Analysis to 2023

AVP-825 (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose...

March 2014
FROM

Visceral Pain - Pipeline Review, H1 2014

Visceral Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Visceral Pain - Pipeline Review, H1 2014’, provides an overview of the Visceral Pain’s therapeutic pipeline. This report...

March 2014
FROM

Chronic Back Pain - Pipeline Review, H1 2014

Chronic Back Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Chronic Back Pain - Pipeline Review, H1 2014’, provides an overview of the Chronic Back Pain’s therapeutic pipeline. This...

March 2014
FROM

Dyskinesia - Pipeline Review, H1 2014

Dyskinesia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Dyskinesia - Pipeline Review, H1 2014’, provides an overview of the Dyskinesia’s therapeutic pipeline. This report provides...

March 2014
FROM

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2014

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2014’, provides an overview of the Bipolar...

March 2014
FROM

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected...

March 2014
FROM

Levadex (Migraine) - Forecast and Market Analysis to 2023

Levadex (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose...

March 2014
FROM
Loading Indicator

Our Clients

Our clients' logos